Pharmascience Inc. has officially formalized the acquisition of its business partner’s shares in South Korea

Pharmascience is proud to announce the acquisition of its partner’s shares (Korea Kolmar Holdings Co. Ltd., in South Korea) of an existing joint venture, making it wholly owned by Pharmascience.

In 2012, Pharmascience and Kolmar established a strategic joint venture partnership, under the Pharmascience Korea banner.

“This strategic investment will allow us to accelerate our short and long-term growth plans in South Korea and expand our regional presence in Asia” says Jacquelin Gagnon, Vice-President & General Manager Pharmascience International. With more than 19 products on the Korean market mainly in the central nervous system and oncology therapeutic areas, this transaction is aligned with our Pharmascience international expansion and growth strategy, introducing high quality pharmaceutical products to patients worldwide. The official acquisition date is June 1, 2021.



Founded in 1983, Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada with over 1,500 employees, and an international presence spanning 50 countries. Pharmascience’s global presence and agile business development model provides patients and healthcare communities around the world with the same high- quality medicines as are dispensed in Canada. Our highly skilled manufacturing, research and development teams deliver expertise in the development of complex injectable and solid oral dose drugs.

Pharmascience manufactures and distributes high-quality FDA approved generic products within our Canadian site. Our commitment to ongoing research and development is fueled by investments of over $500M supporting a diverse product offering of over 300 product families covering an expansive dosage form capability. Recognized as a leader within the Canadian market Pharmascience products fill more than 45 million prescriptions per year.

Published in

Business News